Trials / Completed
CompletedNCT02745223
Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Orasis Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study to establish safety, tolerability, and efficacy of PresbiDrops (CSF-1) in presbyopic subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PresbiDrops (CSF-1) | PresbiDrops (CSF-1) is a topical ophthalmic drug. |
| DRUG | Placebo | Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients. |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-04-20
- Last updated
- 2017-08-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02745223. Inclusion in this directory is not an endorsement.